Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

204884 Complement C3a des-Arg, Human

Complement C3a des-Arg, Human, is a single chain native des-Arg C3 complement component

Complement C3a des-Arg, Human MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
204884
Purchase on Sigma-Aldrich

概述

Replacement Information

Products

产品目录编号包装 数量 / 包装
204884-50UGCN 塑胶安瓿;塑胶针药瓶 50 μg
Description
OverviewNative, human des-Arg C3 complement component. Single chain, 76 amino acid peptide. Once the C3a peptide has been produced in human plasma or serum, it is rapidly converted to C3a des-Arg upon removal of the C-terminal arginine by endogenous serum carboxypeptidase N. This enzymatic process is considered to be a major mechanism for controlling C3a function in vivo because C3a des-Arg has <1% of the biological activity expressed by the C3a peptide. Therefore, C3a des-Arg can serve as a negative control molecule in experiments involved with the biological activities of the intact C3a anaphylatoxin peptide.
Catalogue Number204884
Brand Family Calbiochem®
References
ReferencesKajita, T. and Hugli, T.E. 1991. Am. J. Pathol. 138, 1359.
Bokish, V.A. and Muller-Eberhard, H.J. 1970. J. Clin. Invest. 49, 2427.
Product Information
FormLiquid
FormulationIn PBS, pH 7.2.
Quality LevelMQ100
Applications
Biological Information
Biological activityIleum contraction assay: negative
Purity≥90% by SDS-PAGE
SourcePrepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
Concentration Label Please refer to vial label for lot-specific concentration
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Dry Ice Only
Toxicity Standard Handling
Storage ≤ -70°C
Avoid freeze/thaw Avoid freeze/thaw
Do not freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
产品目录编号 GTIN
204884-50UGCN 04055977219784

Documentation

Complement C3a des-Arg, Human MSDS

职位

物料安全数据表 (MSDS) 

Complement C3a des-Arg, Human 分析证书

标题批号
204884

参考

参考信息概述
Kajita, T. and Hugli, T.E. 1991. Am. J. Pathol. 138, 1359.
Bokish, V.A. and Muller-Eberhard, H.J. 1970. J. Clin. Invest. 49, 2427.
数据表

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision16-December-2018 JSW
DescriptionNative, human des-Arg C3 complement component. Single chain, 76 amino acid peptide. Once the C3a peptide has been produced in human plasma or serum, it is rapidly converted to C3a des-Arg upon removal of the C-terminal arginine by endogenous serum carboxypeptidase N. This enzymatic process is considered to be a major mechanism for controlling C3a function in vivo because C3a des-Arg has <1% of the biological activity expressed by the C3a peptide. Therefore, C3a des-Arg can serve as a negative control molecule in experiments involved with the biological activities of the intact C3a anaphylatoxin peptide.
FormLiquid
FormulationIn PBS, pH 7.2.
Concentration Label Please refer to vial label for lot-specific concentration
SourcePrepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
Purity≥90% by SDS-PAGE
Biological activityIleum contraction assay: negative
Storage Avoid freeze/thaw
≤ -70°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
Toxicity Standard Handling
ReferencesKajita, T. and Hugli, T.E. 1991. Am. J. Pathol. 138, 1359.
Bokish, V.A. and Muller-Eberhard, H.J. 1970. J. Clin. Invest. 49, 2427.